Organicell Regenerative Medicine, Inc. Secures $4 Million In Funding For Clinical Trials And Agrees To Restructure Management

Jul 20, 2022•over 3 years ago

Amount Raised

$4 Million

Round Type

seed

Miami

Description

MIAMI, FL / July 20, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and the provision of related services, announced today that it has secured $4.0 million in funding to finance clinical trials of its products and for general working capital purposes.

Company Information

Company

Organicell Regenerative Medicines

Location

Miami, Florida, United States

About

Organicell Regenerative Medicine, Inc. (OTCQB:OCEL) is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and the provision of other related services. The Company's proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. To learn more, please visit https://organicell.com/.

Related People

3 contacts

Organicell Regenerative Medicine, Inc. Secures $4 Million In Funding For Clinical Trials And Agrees To Restructure Management

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Company Information